Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review.
Astrocytoma
Epilepsy
Glioblastoma
Meningioma
Seizure
Journal
Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
05
02
2024
accepted:
13
02
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
Brain tumors and metastases account for approximately 10% of all status epilepticus (SE) cases. This study described the clinical characteristics, treatment, and short- and long-term outcomes of this population. This retrospective, multi-center cohort study analyzed all brain tumor patients treated for SE at the university hospitals of Frankfurt and Marburg between 2011 and 2017. The 208 patients (mean 61.5 ± 14.7 years of age; 51% male) presented with adult-type diffuse gliomas (55.8%), metastatic entities (25.5%), intracranial extradural tumors (14.4%), or other tumors (4.3%). The radiological criteria for tumor progression were evidenced in 128 (61.5%) patients, while 57 (27.4%) were newly diagnosed with tumor at admission and 113 (54.3%) had refractory SE. The mean hospital length of stay (LOS) was 14.8 days (median 12.0, range 1-57), 171 (82.2%) patients required intensive care (mean LOS 8.9 days, median 5, range 1-46), and 44 (21.2%) were administered mechanical ventilation. All patients exhibited significant functional status decline (modified Rankin Scale) post-SE at discharge (p < 0.001). Mortality at discharge was 17.3% (n = 36), with the greatest occurring in patients with metastatic disease (26.4%, p = 0.031) and those that met the radiological criteria for tumor progression (25%, p < 0.001). Long-term mortality at one year (65.9%) was highest in those diagnosed with adult-type diffuse gliomas (68.1%) and metastatic disease (79.2%). Refractory status epilepticus cases showed lower survival rates than non-refractory SE patients (log-rank p = 0.02) and those with signs of tumor progression (log-rank p = 0.001). SE occurrence contributed to a decline in functional status in all cases, regardless of tumor type, tumor progression status, and SE refractoriness, while long-term mortality was increased in those with malignant tumor entities, tumor progressions, and refractory SE. SE prevention may preserve functional status and improve survival in individuals with brain tumors.
Identifiants
pubmed: 38570823
doi: 10.1186/s42466-024-00314-7
pii: 10.1186/s42466-024-00314-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Informations de copyright
© 2024. The Author(s).
Références
Herman, S. T. (2002). Epilepsy after brain insult: Targeting epileptogenesis. Neurology, 59(9 Suppl 5), S21–S26. https://doi.org/10.1212/wnl.59.9_suppl_5.s21
doi: 10.1212/wnl.59.9_suppl_5.s21
pubmed: 12428028
Olafsson, E., Ludvigsson, P., Hesdorffer, D., Kjartansson, O., Hauser, W. A., & Gudmundsson, G. (2005). Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: A prospective study. The Lancet Neurology., 4(10), 627–634. https://doi.org/10.1016/s1474-4422(05)70172-1
doi: 10.1016/s1474-4422(05)70172-1
pubmed: 16168931
Seidel, S., Wehner, T., Miller, D., Wellmer, J., Schlegel, U., & Gronheit, W. (2022). Brain tumor related epilepsy: Pathophysiological approaches and rational management of antiseizure medication. Neurological Research and Practice., 4(1), 45. https://doi.org/10.1186/s42466-022-00205-9
doi: 10.1186/s42466-022-00205-9
pubmed: 36059029
pmcid: 9442934
Hauser, W. A., Annegers, J. F., & Kurland, L. T. (1993). Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia, 34(3), 453–468. https://doi.org/10.1111/j.1528-1157.1993.tb02586.x
doi: 10.1111/j.1528-1157.1993.tb02586.x
pubmed: 8504780
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007). Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. The Lancet Neurology., 6(5), 421–430. https://doi.org/10.1016/S1474-4422(07)70103-5
doi: 10.1016/S1474-4422(07)70103-5
pubmed: 17434097
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., et al. (2000). Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 54(10), 1886–1893. https://doi.org/10.1212/wnl.54.10.1886
doi: 10.1212/wnl.54.10.1886
pubmed: 10822423
Maschio, M. (2012). Brain tumor-related epilepsy. Current Neuropharmacology, 10(2), 124–133. https://doi.org/10.2174/157015912800604470
doi: 10.2174/157015912800604470
pubmed: 23204982
pmcid: 3386502
Rossetti, A. O., & Stupp, R. (2010). Epilepsy in brain tumor patients. Current Opinion in Neurology., 23(6), 603–609. https://doi.org/10.1097/WCO.0b013e32833e996c
doi: 10.1097/WCO.0b013e32833e996c
pubmed: 20733482
Goonawardena, J., Marshman, L. A., & Drummond, K. J. (2015). Brain tumour-associated status epilepticus. Journal of Clinical Neuroscience, 22(1), 29–34. https://doi.org/10.1016/j.jocn.2014.03.038
doi: 10.1016/j.jocn.2014.03.038
pubmed: 25150762
Betjemann, J. P., & Lowenstein, D. H. (2015). Status epilepticus in adults. The Lancet Neurology., 14(6), 615–624. https://doi.org/10.1016/S1474-4422(15)00042-3
doi: 10.1016/S1474-4422(15)00042-3
pubmed: 25908090
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., et al. (2015). A definition and classification of status epilepticus–report of the ILAE task force on classification of status Epilepticus. Epilepsia, 56(10), 1515–1523. https://doi.org/10.1111/epi.13121
doi: 10.1111/epi.13121
pubmed: 26336950
Kamppi, L., Mustonen, H., Kotisaari, K., & Soinila, S. (2018). The essence of the first 25 h in the treatment of generalized convulsive status epilepticus. Seizure., 55, 9–16. https://doi.org/10.1016/j.seizure.2017.12.007
doi: 10.1016/j.seizure.2017.12.007
pubmed: 29306214
Bauer, K., Rosenow, F., Knake, S., Willems, L. M., Kamppi, L., & Strzelczyk, A. (2023). Clinical characteristics and outcomes of patients with recurrent status epilepticus episodes. Neurological Research and Practice, 5(1), 34. https://doi.org/10.1186/s42466-023-00261-9
doi: 10.1186/s42466-023-00261-9
pubmed: 37438822
pmcid: 10339656
Giovannini, G., Pasini, F., Orlandi, N., Mirandola, L., & Meletti, S. (2019). Tumor-associated status epilepticus in patients with glioma: Clinical characteristics and outcomes. Epilepsy & Behavior., 101(Pt B), 106370. https://doi.org/10.1016/j.yebeh.2019.06.014
doi: 10.1016/j.yebeh.2019.06.014
Arik, Y., Leijten, F. S., Seute, T., Robe, P. A., & Snijders, T. J. (2014). Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: A systematic review and meta-analysis. BMC Neurology., 14, 152. https://doi.org/10.1186/1471-2377-14-152
doi: 10.1186/1471-2377-14-152
pubmed: 25037845
pmcid: 4108966
Cavaliere, R., Farace, E., & Schiff, D. (2006). Clinical implications of status epilepticus in patients with neoplasms. Archives of Neurology., 63(12), 1746–1749. https://doi.org/10.1001/archneur.63.12.1746
doi: 10.1001/archneur.63.12.1746
pubmed: 17172614
Purwien, L., Schubert-Bast, S., Kieslich, M., Ronellenfitsch, M. W., Merker, M., Czabanka, M., et al. (2023). Trends and differences in status epilepticus treatment of children and adults over 10 years: A comparative study of medical records (2012–2021) from a University Hospital in Germany. CNS Drugs, 37(11), 993–1008. https://doi.org/10.1007/s40263-023-01049-w
doi: 10.1007/s40263-023-01049-w
pubmed: 37979095
pmcid: 10667152
Knake, S., Rosenow, F., Vescovi, M., Oertel, W. H., Mueller, H. H., Wirbatz, A., et al. (2001). Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia, 42(6), 714–718. https://doi.org/10.1046/j.1528-1157.2001.01101.x
doi: 10.1046/j.1528-1157.2001.01101.x
pubmed: 11422324
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C., Vandenbroucke, J. P., et al. (2007). The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet, 370(9596), 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X
doi: 10.1016/S0140-6736(07)61602-X
Ferlisi, M., & Shorvon, S. (2012). The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain, 135(Pt 8), 2314–2328. https://doi.org/10.1093/brain/aws091
doi: 10.1093/brain/aws091
pubmed: 22577217
Shorvon, S., & Ferlisi, M. (2011). The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain, 134(Pt 10), 2802–2818.
doi: 10.1093/brain/awr215
pubmed: 21914716
Malter, M. P., & Neuneier, J. (2022). Super-refractory status epilepticus in adults. Neurological Research and Practice, 4(1), 35. https://doi.org/10.1186/s42466-022-00199-4
doi: 10.1186/s42466-022-00199-4
pubmed: 35989337
pmcid: 9394073
Leitinger, M., Trinka, E., Gardella, E., Rohracher, A., Kalss, G., Qerama, E., et al. (2016). Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: A retrospective study. The Lancet Neurology., 15(10), 1054–1062. https://doi.org/10.1016/S1474-4422(16)30137-5
doi: 10.1016/S1474-4422(16)30137-5
pubmed: 27571157
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases., 40(5), 373–383.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Banks, J. L., & Marotta, C. A. (2007). Outcomes validity and reliability of the modified Rankin scale: Implications for stroke clinical trials: A literature review and synthesis. Stroke, 38(3), 1091–1096. https://doi.org/10.1161/01.STR.0000258355.23810.c6
doi: 10.1161/01.STR.0000258355.23810.c6
pubmed: 17272767
Rossetti, A. O., Logroscino, G., Milligan, T. A., Michaelides, C., Ruffieux, C., & Bromfield, E. B. (2008). Status Epilepticus Severity Score (STESS): A tool to orient early treatment strategy. Journal of Neurology., 255(10), 1561–1566. https://doi.org/10.1007/s00415-008-0989-1
doi: 10.1007/s00415-008-0989-1
pubmed: 18769858
Beuchat, I., Rosenow, F., Kellinghaus, C., Trinka, E., Unterberger, I., Ruegg, S., et al. (2022). Refractory status epilepticus: Risk factors and analysis of intubation in the multicenter SENSE registry. Neurology, 99(16), e1824–e1834. https://doi.org/10.1212/WNL.0000000000201099
doi: 10.1212/WNL.0000000000201099
pubmed: 35948449
Cornwall, C. D., Kroigard, T., Kristensen, J. S. S., Callesen, H. E., & Beier, C. P. (2023). Outcomes and treatment approaches for super-refractory status epilepticus: A systematic review and meta-analysis. JAMA Neurology., 80(9), 959–968. https://doi.org/10.1001/jamaneurol.2023.2407
doi: 10.1001/jamaneurol.2023.2407
pubmed: 37523161
Guterman, E. L., Betjemann, J. P., Aimetti, A., Li, J. W., Wang, Z., Yin, D., et al. (2021). Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurology., 78(5), 588–595. https://doi.org/10.1001/jamaneurol.2021.0520
doi: 10.1001/jamaneurol.2021.0520
pubmed: 33818596
Beuchat, I., Novy, J., Rosenow, F., Kellinghaus, C., Ruegg, S., Tilz, C., et al. (2024). Staged treatment response in status epilepticus: Lessons from the SENSE registry. Epilepsia, 65(2), 338-349. https://doi.org/10.1111/epi.17817
doi: 10.1111/epi.17817
pubmed: 37914525
Lattanzi, S., & Meletti, S. (2024). Refractory status epilepticus: Is there room for grading refractoriness? Epilepsia, 65(2), 527-528. https://doi.org/10.1111/epi.17836
doi: 10.1111/epi.17836
pubmed: 38339985
Rossetti, A. O., Hurwitz, S., Logroscino, G., & Bromfield, E. B. (2006). Prognosis of status epilepticus: Role of aetiology, age, and consciousness impairment at presentation. Journal of Neurology, Neurosurgery and Psychiatry, 77(5), 611–615. https://doi.org/10.1136/jnnp.2005.080887
doi: 10.1136/jnnp.2005.080887
pubmed: 16614020
pmcid: 2117456
Kaneoka, A., Fujimoto, S. H., Tamura, K., Inaji, M., & Maehara, T. (2023). Nonconvulsive status epilepticus characteristics in glioma patients: A retrospective study. Discover Oncology, 14(1), 30. https://doi.org/10.1007/s12672-023-00632-3
doi: 10.1007/s12672-023-00632-3
pubmed: 36881187
pmcid: 9992690
Vilaseca-Jolonch, A., Abraira, L., Quintana, M., Sueiras, M., Thonon, V., Toledo, M., et al. (2020). Tumor-associated status epilepticus: A prospective cohort in a tertiary hospital. Epilepsy & Behavior., 111, 107291. https://doi.org/10.1016/j.yebeh.2020.107291
doi: 10.1016/j.yebeh.2020.107291
Fox, J., Ajinkya, S., Greenblatt, A., Houston, P., Lekoubou, A., Lindhorst, S., et al. (2019). Clinical characteristics, EEG findings and implications of status epilepticus in patients with brain metastases. Journal of the Neurological Sciences, 407, 116538. https://doi.org/10.1016/j.jns.2019.116538
doi: 10.1016/j.jns.2019.116538
pubmed: 31644990
Knudsen-Baas, K. M., Power, K. N., Engelsen, B. A., Hegrestad, S. E., Gilhus, N. E., & Storstein, A. M. (2016). Status epilepticus secondary to glioma. Seizure., 40, 76–80. https://doi.org/10.1016/j.seizure.2016.06.013
doi: 10.1016/j.seizure.2016.06.013
pubmed: 27367838
Marcuse, L. V., Lancman, G., Demopoulos, A., & Fields, M. (2014). Nonconvulsive status epilepticus in patients with brain tumors. Seizure., 23(7), 542–547. https://doi.org/10.1016/j.seizure.2014.04.003
doi: 10.1016/j.seizure.2014.04.003
pubmed: 24810208
Rosati, A., Tomassini, A., Pollo, B., Ambrosi, C., Schwarz, A., Padovani, A., et al. (2009). Epilepsy in cerebral glioma: Timing of appearance and histological correlations. Journal of Neuro-oncology, 93(3), 395–400. https://doi.org/10.1007/s11060-009-9796-5
doi: 10.1007/s11060-009-9796-5
pubmed: 19183850
Kortland, L. M., Knake, S., von Podewils, F., Rosenow, F., & Strzelczyk, A. (2017). Socioeconomic outcome and quality of life in adults after status epilepticus: A multicenter, longitudinal, matched case-control analysis from Germany. Frontiers in Neurology., 8, 507. https://doi.org/10.3389/fneur.2017.00507
doi: 10.3389/fneur.2017.00507
pubmed: 29018404
pmcid: 5622933
Roberg, L. E., Monsson, O., Kristensen, S. B., Dahl, S. M., Ulvin, L. B., Heuser, K., et al. (2022). Prediction of long-term survival after status epilepticus using the ACD score. JAMA Neurology., 79(6), 604–613. https://doi.org/10.1001/jamaneurol.2022.0609
doi: 10.1001/jamaneurol.2022.0609
pubmed: 35404392
pmcid: 9002715
Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. H., & Rosenow, F. (2017). Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Epilepsia, 58(9), 1533–1541. https://doi.org/10.1111/epi.13837
doi: 10.1111/epi.13837
pubmed: 28681418
Brauchitsch, S., Strzelczyk, A., Rosenow, F., Neuhaus, E., Dubinski, D., Steinbach, J.P., Voss M. (2022) High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors. Journal of Neuro-Oncology, 160(2), 277–284. https://doi.org/10.1007/s11060-022-04133-1
doi: 10.1007/s11060-022-04133-1
pubmed: 36329367
pmcid: 9722831
Kortland, L. M., Alfter, A., Bahr, O., Carl, B., Dodel, R., Freiman, T. M., et al. (2016). Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia, 57(12), 2056–2066. https://doi.org/10.1111/epi.13584
doi: 10.1111/epi.13584
pubmed: 27753082
Mevius, A., Joeres, L., Gille, P., Molzan, M., Foskett, N., Wilke, T., et al. (2023). Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: Insights from a large healthcare database. Brain Commun., 5(3), fcad145. https://doi.org/10.1093/braincomms/fcad145
doi: 10.1093/braincomms/fcad145
pubmed: 37180995
pmcid: 10174205
Urban, H., Willems, L. M., Ronellenfitsch, M. W., Rosenow, F., Steinbach, J. P., & Strzelczyk, A. (2020). Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition. Oncoimmunology., 9(1), 1851517. https://doi.org/10.1080/2162402X.2020.1851517
doi: 10.1080/2162402X.2020.1851517
pubmed: 33299662
pmcid: 7714514